公开(公告)号：CA2950485A1

公开(公告)日：2016-01-07

申请号：CA2950485

申请日：2015-06-24

Applicant: BASF SE

Inventor： VIERTELHAUS MARTIN ,  CHIODO TIZIANA ,  SALVADOR BEATE ,  VOSSEN MARCUS ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  SZELAGIEWICZ MARTIN ,  BLATTER FRITZ

IPC: C07D417/12 ,  A61K31/506

Abstract: The present invention primarily relates to multicomponent crystals comprising a compound of formula 1 and a second compound selected from the group consisting of menthol and vanillin. The invention is further related to pharmaceutical compositions comprising such multicomponent crystals. Furthermore, the invention relates to processes for preparing said multicomponent crystals. The invention also relates to several aspects of using said multicomponent crystals or pharmaceutical compositions to treat a disease.

公开(公告)号：MX2014015433A

公开(公告)日：2015-09-16

申请号：MX2014015433

申请日：2013-06-13

Applicant: BASF SE

Inventor： SZELAGIEWICZ MARTIN ,  BLATTER FRITZ ,  CHIODO TIZIANA ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  SIEBENHAAR BERND ,  VOSSEN MARCUS

IPC: C07D417/12 ,  A61K31/506 ,  A61P35/00

Abstract: La presente invención se refiere a un sistema cristalino de componentes múltiples (co-cristal) que comprende un compuesto de la fórmula I (INN: Dasatinib) y un segundo compuesto seleccionado de metil-4-hidroxibenzoato, o nicotinamida, o galato de etilo, o galato de metilo, o galato de propilo, o etil maltol o vainillina, o mentol, o (1R,2S,5R)-(-), así como a un procedimiento para obtener el mismo.

公开(公告)号：CA2917183A1

公开(公告)日：2015-01-29

申请号：CA2917183

申请日：2014-07-22

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

IPC: A61K31/506 ,  A61K31/191 ,  A61K31/428 ,  A61K31/455

Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

公开(公告)号：CA2879792A1

公开(公告)日：2014-02-13

申请号：CA2879792

申请日：2013-08-05

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  RODEL EVA ,  SZELAGIEWICZ MARTIN ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

IPC: C07D249/08 ,  A61K31/4196 ,  A61P7/00

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN:Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.

公开(公告)号：AU2013333953A1

公开(公告)日：2015-04-30

申请号：AU2013333953

申请日：2013-10-16

Applicant: BASF SE

Inventor： CHIODO TIZIANA ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  SZELAGIEWICZ MARTIN ,  BLATTER FRITZ ,  RODEL EVA ,  VOSSEN MARCUS

IPC: C07D401/14 ,  A61K31/506 ,  A61P35/02

Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.

公开(公告)号：CA2887540A1

公开(公告)日：2014-04-24

申请号：CA2887540

申请日：2013-10-16

Applicant: BASF SE

Inventor： CHIODO TIZIANA ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  SZELAGIEWICZ MARTIN ,  BLATTER FRITZ ,  RODEL EVA ,  VOSSEN MARCUS

IPC: C07D401/14 ,  A61K31/506 ,  A61P35/02

Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.

公开(公告)号：CA2876539A1

公开(公告)日：2013-12-19

申请号：CA2876539

申请日：2013-06-13

Applicant: BASF SE

Inventor： CHIODO TIZIANA ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  SZELAGIEWICZ MARTIN ,  BLATTER FRITZ ,  SIEBENHAAR BERND ,  VOSSEN MARCUS

IPC: C07D417/12 ,  A61K31/506 ,  A61P35/00

Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (lR,2S,5R)-(-)- menthol.

公开(公告)号：AU2014295143B9

公开(公告)日：2017-03-23

申请号：AU2014295143

申请日：2014-07-22

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

IPC: C07D417/12

Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

公开(公告)号：AU2014295143B2

公开(公告)日：2017-03-16

申请号：AU2014295143

申请日：2014-07-22

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

IPC: C07D417/12

Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

公开(公告)号：CA2955570A1

公开(公告)日：2016-02-11

申请号：CA2955570

申请日：2015-08-03

Applicant: BASF SE

Inventor： VIERTELHAUS MARTIN ,  CHIODO TIZIANA ,  SALVADOR BEATE ,  VOSSEN MARCUS ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  WEISHAAR WALTER ,  HELLMANN ROLF

IPC: C07D213/40

Abstract: The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and sol-vents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.